SPR720

DRUG3 trials

Sponsors

Spero Therapeutics

Conditions

Healthy VolunteerHealthy VolunteersMycobacterium Avium ComplexNon-tuberculous Mycobacterium Pulmonary Disease

Phase 1

A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.

CompletedNCT05955586

Spero TherapeuticsHealthy Volunteer

Start: 2023-08-01End: 2024-02-23Updated: 2024-03-07

A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants

CompletedNCT05966688

Spero TherapeuticsHealthy Volunteers

Start: 2023-08-04End: 2024-02-04Updated: 2024-03-04

Phase 2

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

TerminatedNCT04553406

Spero TherapeuticsMycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease

Start: 2020-12-03End: 2021-01-28Updated: 2022-02-28

Related Papers

Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers

Antimicrobial Agents and Chemotherapy2024-10-011 citations